Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Gilead Mulling Japan Entry into PIII Study for Inhaled Version of Veklury
February 5, 2021
-
BUSINESS Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
February 4, 2021
-
REGULATORY Celgene’s Liso-Cel Up for PAFSC Review on Feb. 17, 3rd CAR-T Therapy in Japan
February 4, 2021
-
BUSINESS Eisai Neurology Chief Says Partners Continue to Stand Behind Aducanumab
February 4, 2021
-
ORGANIZATION PhRMA Prods Japan to Harness Power of RWD in Drug Development, Medical Care Evaluation
February 3, 2021
-
REGULATORY Japan Moves Up Vaccine Rollout Target to Mid-February, PAFSC Review on Feb. 12?
February 3, 2021
-
INTERVIEW Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
-
BUSINESS Teijin to Acquire Fujifilm's J-TEC for Up to 21.6 Billion Yen
February 1, 2021
-
BUSINESS FDA Delays Decision for Biogen’s Aducanumab to June 7
February 1, 2021
-
REGULATORY MHLW Wants to Encourage Non-Monitoring Facilities to Report Inappropriate Drug Promotion
January 29, 2021
-
BUSINESS Kobayashi Kako Issues Yet Another Recall, Now for 12 APIs/21 Products
January 28, 2021
-
REGULATORY Kobayashi Kako Might Face 116-Day Biz Suspension over Drug Mix-Up
January 27, 2021
-
REGULATORY Kobayashi Kako Notified of Record Biz Suspension of 110-Plus Days over Drug Mix-Up
January 26, 2021
-
REGULATORY MHLW Approves Sakigake-Designated HAE Treatment, Lilly’s Migraine Med, Takeda’s Alunbrig, Ono’s Cachexia Drug, and More
January 25, 2021
-
BUSINESS Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
-
BUSINESS Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
-
REGULATORY Kobayashi Kako Submits Report on Drug Mix-Up, Could Face Administrative Penalty in 1st Half of February
January 21, 2021
-
REGULATORY Japan, Pfizer Finalize COVID-19 Vaccine Deal, Agree on Supply of 144 Million Doses
January 21, 2021
-
BUSINESS Will Cymbalta, E Keppra Face Generic Competition This Year? Vesicare, Aloxi Too?
January 20, 2021
-
REGULATORY MHLW Eyes 1st Revision of Drug Industry Vision in 8 Years as Off-Year Re-Pricing Takes Shape: Official
January 19, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…